Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
Status:
Recruiting
Trial end date:
2026-09-22
Target enrollment:
Participant gender:
Summary
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder
in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants
delivered by MOMs participants will be offered the opportunity to enroll in this sub-study,
which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative
to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data
collected in this sub-study will be combined with data from the main MOMs trial.
Phase:
Phase 3
Details
Lead Sponsor:
T. John Winhusen, PhD Theresa Winhusen, PhD
Collaborators:
National Institute on Drug Abuse (NIDA) The Emmes Company, LLC The EMMES Corporation